Twist Antibody Optimization (TAO)

Delivering fully human optimized lead antibodies with higher affinity and lower risk

 

Contact Us

Driven by Our Proprietary TAO Software

Simply input your murine, chimeric, humanized, or fully human antibody sequence, and our algorithm will optimize and humanize your sequence into a “human repertoire inspired” phage display library.

Learn More

Downstream Liabilities Removed

Humanize Any Antibody Input Sequence

Quickly Improve Affinty

Writing the Next Chapter in Antibody Therapeutics

Built with Precision DNA Synthesis

Our rapid, scalable DNA synthesis platform enables us to quickly generate defined synthetic libraries. We convert your parental antibody to the closest germline sequence and comprehensively explore the mutational space with unprecedented efficiency.

End-to-End Support for Antibody Development

Our DNA synthesis capabilities also enable us to offer high-throughput conversion from scFv, Fab, or VHH formats to full-length IgG. Our team of antibody experts leverages their collective 50 years of experience to streamline development, with biochemical, biophysical, and functional screening of any TAO antibodies.

End-to-End Support for Antibody Development
Watch the Webinar

Watch the Webinar

Developing Therapeutics Against Virtually Any Target with New Antibody Libraries

Watch it

What Scientists Have to Say
Twist’s unique ability to generate robust, diverse and cutting-edge libraries through its proprietary silicon platform together with our deep insight into therapeutic drug discovery and development will help us expand a growing pipeline of targeted biologic candidates.
Robert Mabry
Head of Global Biologics Research, Takeda
Twist is the only synthetic DNA provider who can deliver the quantity and quality of DNA we need for our projects rapidly. We are working with them not only as a vendor for synthetic genes and antibodies, but have expanded our relationship to leverage the Twist Biopharma capabilities, which we believe complement our antibody discovery efforts.
Robert Carnahan, PhD
Associate Director of the Vanderbilt Vaccine Center